September 7, 2022
University of Cincinnati researchers recently published study results in JAMA Otolaryngology showing that administering immunotherapy drug pembrolizumab before surgery for oral cavity cancer did not increase rates of complication during and after surgery.
March 28, 2023
Researchers led by the University of Cincinnati's Nalinikanth Kotagiri, PhD, have published new research showing proof of concept for using engineered bacteria as an adapter to deliver targeted radionuclide treatment to tumors.
March 28, 2023
Treatment of the first patient in a clinical trial of FLASH proton therapy for cancers in the bones of the chest has been completed at the Cincinnati Children’s/University of Cincinnati Medical Center Proton Therapy Center.
April 3, 2023
University of Cincinnati researchers recently published findings in the journal Cancer that found several enriched species, associated with enhanced tumor immune response, in the microbiomes of long-term pancreatic cancer survivors.
April 11, 2023
The University of Cincinnati's Atsuo Sasaki, PhD, is leading a multidisciplinary team that received National Institutes of Health funding to learn more about how an enzyme that was previously overlooked helps regulate lysosome and cellular function.
May 19, 2023
The University of Cincinnati Cancer Center's Syed Ahmad, MD, is the national principal investigator for a phase 2 trial testing the effectiveness of chemotherapy treatment following surgery for a subset of pancreatic cancer patients.
May 26, 2023
University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Clinical Oncology (ASCO) annual meeting 2023, held in Chicago June 2-6.
October 24, 2022
University of Cincinnati researchers presented results from the first-in-human trial of FLASH radiotherapy at the ASTRO 2022 annual meeting, with data suggesting FLASH may hold promise as a potential treatment for tough-to-kill tumors.
November 3, 2022
The University of Cincinnati's Trisha Wise-Draper, MD, PhD, is co-corresponding author of new research in JAMA Oncology that provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
March 21, 2023
Amanda Jackson, MD, is the site principal investigator at the University of Cincinnati for the UP-NEXT trial that is testing a new treatment for a subset of ovarian cancer patients.